Unbound Cloxacillin Concentrations During Continuous Infusion
Concentration of Unbound Cloxacillin in Adults Treated With Continuous Infusion Via Elastomeric Pump
Emeli Månsson
25 participants
Jan 14, 2026
INTERVENTIONAL
Conditions
Summary
Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06848387